Analysts Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $17.60

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has been given an average recommendation of “Hold” by the eight brokerages that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $17.60.

Several research firms recently commented on AMLX. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. The Goldman Sachs Group increased their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Friday, July 12th.

Amylyx Pharmaceuticals Trading Up 2.6 %

Shares of AMLX stock opened at $3.55 on Monday. Amylyx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $19.95. The business’s 50-day moving average price is $2.55 and its 200-day moving average price is $2.17. The firm has a market capitalization of $241.42 million, a price-to-earnings ratio of -3.32 and a beta of -0.55.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The firm had revenue of ($1.02) million for the quarter, compared to the consensus estimate of $18.83 million. During the same period last year, the company posted $0.31 EPS. On average, sell-side analysts predict that Amylyx Pharmaceuticals will post -2.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Camille L. Bedrosian sold 11,442 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $3.20, for a total transaction of $36,614.40. Following the transaction, the insider now directly owns 143,801 shares of the company’s stock, valued at $460,163.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Camille L. Bedrosian sold 11,442 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $3.20, for a total transaction of $36,614.40. Following the completion of the sale, the insider now directly owns 143,801 shares of the company’s stock, valued at $460,163.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Justin B. Klee sold 18,589 shares of the company’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $3.20, for a total transaction of $59,484.80. Following the completion of the sale, the chief executive officer now owns 3,120,569 shares in the company, valued at $9,985,820.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.70% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several institutional investors have recently bought and sold shares of AMLX. Vanguard Group Inc. lifted its stake in Amylyx Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,348,139 shares of the company’s stock valued at $15,189,000 after acquiring an additional 72,573 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Amylyx Pharmaceuticals by 2,768.0% during the second quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company’s stock valued at $6,348,000 after purchasing an additional 3,224,454 shares in the last quarter. Almitas Capital LLC purchased a new position in Amylyx Pharmaceuticals in the second quarter worth $3,617,000. Goldman Sachs Group Inc. grew its stake in Amylyx Pharmaceuticals by 5.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,256,861 shares of the company’s stock valued at $18,501,000 after purchasing an additional 69,733 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $2,300,000. Institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.